Evidence map›Paper›PMID 35251016›Full record

ArticleFrontiers in immunology2022

A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China.

Ziyuan Shen, Yingliang Jin, Qian Sun, Shuo Zhang, Xi Chen, Lingling Hu, Chenlu He, Ying Wang, Qinhua Liu, Hao Zhang and 22 more

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Ziyuan ShenDepartment of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Yingliang JinCenter for Medical Statistics and Data Analysis, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Qian SunDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shuo ZhangDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xi ChenDepartment of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Lingling HuDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chenlu HeDepartment of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Ying WangDepartment of Personnel, Suqian First Hospital, Suqian, China.
Qinhua LiuDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hao ZhangDepartment of Hematology, The Affiliated Hospital of Jining Medical University, Jining, China.
Xin LiuDepartment of Hematology, The Affiliated Hospital of Jining Medical University, Jining, China.
Ling WangDepartment of Hematology, Taian Central Hospital, Taian, China.
Jun JiaoDepartment of Hematology, Taian Central Hospital, Taian, China.
Yuqing MiaoDepartment of Hematology, Yancheng First People's Hospital, Yancheng, China.
Weiying GuDepartment of Hematology, The First People's Hospital of Changzhou, Changzhou, China.
Fei WangDepartment of Hematology, The First People's Hospital of Changzhou, Changzhou, China.
Chunling WangDepartment of Hematology, Huai'an First People's Hospital, Huai'an, China.
Yuye ShiDepartment of Hematology, Huai'an First People's Hospital, Huai'an, China.
Jingjing YeDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Taigang ZhuDepartment of Hematology, The General Hospital of Wanbei Coal-Electric Group, Suzhou, China.
Cai SunDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xuguang SongDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Linyan XuDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Dongmei YanDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Haiying SunDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jiang CaoDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Depeng LiDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhenyu LiDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhao WangDepartment of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Shuiping HuangCenter for Medical Statistics and Data Analysis, School of Public Health, Xuzhou Medical University, Xuzhou, China.
Kailin XuDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wei SangDepartment of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is an immune disorder with rapid progression and poor survival. Individual treatment strategy is restricted, due to the absence of precise stratification criteria. In this multicenter retrospective study, we aimed to develop a feasible prognostic model for adult HLH in China. A total of 270 newly diagnosed patients of adult HLH were retrieved from the Huaihai Lymphoma Working Group (HHLWG), of whom 184 from 5 medical centers served as derivation cohort, and 86 cases from 3 other centers served as validation cohort. X-Tile program and Maxstat analysis were used to identify optimal cutoff points of continuous variables; univariate and multivariate Cox analyses were used for variable selection, and the Kaplan-Meier curve was used to analyze the value of variables on prognosis. The C-index, Brier Score, and calibration curve were used for model validation. Multivariate analysis showed that age, creatinine, albumin, platelet, lymphocyte ratio, and alanine aminotransferase were independent prognostic factors. By rounding up the hazard ratios from 6 significant variables, a maximum of 9 points was assigned. The final scoring model of HHLWG-HPI was identified with four risk groups: low risk (≤3 pts), low-intermediate risk (4 pts), high-intermediate risk (5-6 pts), and high risk (≥7 pts), with 5-year overall survival rates of 68.5%, 35.2%, 21.3%, and 10.8%, respectively. The C-indexes were 0.796 and 0.758 in the derivation and validation cohorts by using a bootstrap resampling program. In conclusion, the HHLWG-HPI model provides a feasible and accurate stratification system for individualized treatment strategy in adult HLH.

Indexed as

Lymphohistiocytosis, HemophagocyticLymphomaAdultHumansPrognosisProportional Hazards ModelsRetrospective StudiesSurvival Rateadulthemophagocytic lymphohistiocytosismulticenterprognostic modelstratification

Identifiers

PMID35251016
PMCPMC8894441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.